Advertisement

Endoscopic Management of Achalasia: Botulinum Toxin and Pneumatic Dilation

  • Michael F. VaeziEmail author
  • Brian M. Lappas
Chapter

Abstract

Achalasia is the most common primary motility disorder of the esophagus and is characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent peristalsis of the esophageal body during deglutition. It can cause significant morbidity with symptoms of dysphagia, regurgitation, chest pain, and weight loss. As there is no cure for achalasia, treatments should aim to relieve symptoms and prevent disease progression. Two of the most common endoscopic treatment options are botulinum toxin injection and pneumatic dilation. Botulinum toxin injection is an excellent option for elderly or high-risk surgical patients although repeat injections are often needed after 1 year. Pneumatic dilation is the most effective nonoperative treatment option and provides excellent symptom relief up to 10 years. Both methods have low complication rates, and patients may be discharged after a short period of observation.

Keywords

Achalasia Botulinum toxin Pneumatic dilation Endoscopy Endoscopic dilation Botox injection Esophageal dysmotility Dysphagia 

Notes

Conflict of Interest

Dr. Vaezi has a research grant from Sandhill Scientific, Inc. (Denver, Co, USA). Dr. Lappas has no COI.

References

  1. 1.
    Vaezi MF, Richter JE. Diagnosis and management of achalasia. Am J Gastroenterol. 1999;94(12):3406–1.CrossRefGoogle Scholar
  2. 2.
    Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology. 2010;139(2):369–74.CrossRefGoogle Scholar
  3. 3.
    Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108(8):1238–49.CrossRefGoogle Scholar
  4. 4.
    Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE. The Chicago classification of esophageal motility disorders, v3. 0. Neurogastroenterol Motil. 2015;27(2):160–74.CrossRefGoogle Scholar
  5. 5.
    Leeuwenburgh I, Scholten P, Alderliesten J, Tilanus HW, Looman CW, Steijerberg EW, Kuipers EJ. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol. 2010;105(10):2144–9.CrossRefGoogle Scholar
  6. 6.
    Clark SB, Rice TW, Tubbs RR, Richter JE, Goldblum JR. The nature of the myenteric infiltrate in achalasia: an immunohistochemical analysis. Am J Surg Pathol. 2000;24(8):1153–8.CrossRefGoogle Scholar
  7. 7.
    Goldblum JR, Rice TW, Richter JE. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology. 1996;111(3):648–54.CrossRefGoogle Scholar
  8. 8.
    Villanacci V, Annese V, Cuttitta A, Fisogni S, Scaramuzzi G, De Santo E, Corazzi N, Bassotti G. An immunohistochemical study of the myenteric plexus in idiopathic achalasia. J Clin Gastroenterol. 2010;44(6):407–10.PubMedGoogle Scholar
  9. 9.
    Boeckxstaens GE. Achalasia: virus-induced euthanasia of neurons & quest. Am J Gastroenterol. 2008;103(7):1610–2.CrossRefGoogle Scholar
  10. 10.
    Kim YJ, Kim JH, Lee KJ, Choi MM, Kim YH, Rhie GE, Yoo CK, Cha K, Shin NR. Botulinum neurotoxin type a induces TLR2-mediated inflammatory responses in macrophages. PLoS One. 2015;10(4):e0120840.CrossRefGoogle Scholar
  11. 11.
    Mashimo H. Botulinum toxin for achalasia. Cham: Springer; 2016. p. 31–8.Google Scholar
  12. 12.
    Pasricha P, Ravich W, Kalloo A. Botulinum toxin for achalasia. Lancet. 1993;341(8839):244–5.CrossRefGoogle Scholar
  13. 13.
    Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Treatment of achalasia with intrasphincteric injection of botulinum toxin: a pilot trial. Ann Intern Med. 1994;121(8):590–1.CrossRefGoogle Scholar
  14. 14.
    Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761–8.CrossRefGoogle Scholar
  15. 15.
    Pasricha PJ, Rai RU, Ravich WJ, Hendrix TR, Kalloo AN. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110(5):1410–5.CrossRefGoogle Scholar
  16. 16.
    Zaninotto G, Annese V, Costantini M, Del Genio A, Costantino M, Epifani M, Gatto G, D’onofrio V, Benini L, Contini S, Molena D. Randomized controlled trial of botulinum toxin versus laparoscopic Heller myotomy for esophageal achalasia. Ann Surg. 2004;239(3):364–70.CrossRefGoogle Scholar
  17. 17.
    Vaezi MF, Richter JE, Wilcox CM, Schroeder PL, Birgisson S, Slaughter RL, Koehler RE, Baker ME. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut. 1999;44(2):231–9.CrossRefGoogle Scholar
  18. 18.
    Annese V, Bassotti G, Coccia G, Dinelli M, D’Onofrio V, Gatto G, Leandro G, Repici A, Testoni PA, Andriulli A. GISMAD achalasia study group. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut. 2000;46(5):597–600.CrossRefGoogle Scholar
  19. 19.
    Achkar E. Achalasia. Gastroenterologist. 1995;3(4):273–88.PubMedGoogle Scholar
  20. 20.
    Sweet MP, Nipomnick I, Gasper WJ, Bagatelos K, Ostroff JW, Fisichella PM, Way LW, Patti MG. The outcome of laparoscopic Heller myotomy for achalasia is not influenced by the degree of esophageal dilatation. J Gastrointest Surg. 2008;12(1):159–65.CrossRefGoogle Scholar
  21. 21.
    Mac Iver R, Liptay M, Johnson Y. A case of mediastinitis following botulinum toxin type a treatment for achalasia. Nat Clin Pract Gastroenterol Hepatol. 2007;4(10):579–82.CrossRefGoogle Scholar
  22. 22.
    Wang L, Li YM, Li L, Yu CH. A systematic review and meta-analysis of the Chinese literature for the treatment of achalasia. World J Gastroenterol. 2008;14(38):5900–6.CrossRefGoogle Scholar
  23. 23.
    Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev. 2006;(4):CD005046.Google Scholar
  24. 24.
    Tolone S, Limongelli P, del Genio G, Brusciano L, Russo A, Cipriano L, Terribile M, Docimo G, Ruggiero R, Docimo L. Recent trends in endoscopic management of achalasia. World J Gastrointest Endosc. 2014;6(9):407.CrossRefGoogle Scholar
  25. 25.
    Cox J, Buckton GK, Bennett JR. Balloon dilatation in achalasia: a new dilator. Gut. 1986;27(8):986.CrossRefGoogle Scholar
  26. 26.
    Kadakia SC, Wong RK. Graded pneumatic dilation using Rigiflex achalasia dilators in patients with primary esophageal achalasia. Am J Gastroenterol. 1993;88(1):34–8.PubMedGoogle Scholar
  27. 27.
    Lambroza A, Schuman R. Pneumatic dilation for achalasia without fluoroscopic guidance: safety and efficacy. Gastrointest Endosc. 1995;41(4):354.CrossRefGoogle Scholar
  28. 28.
    Thomas V, Harish K, Sunilkumar K. Pneumatic dilation of achalasia cardia under direct endoscopy: the debate continues. Gastrointest Endosc. 2006;63(4):734.CrossRefGoogle Scholar
  29. 29.
    Vela MF, Richter JE, Khandwala F, Blackstone EH, Wachsberger D, Baker ME, Rice TW. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol. 2006;4(5):580–7.CrossRefGoogle Scholar
  30. 30.
    Vaezi MF, Richter JE. Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol. 1998;27(1):21–35.CrossRefGoogle Scholar
  31. 31.
    Torbey CF, Achkar E, Rice TW, Baker M, Richter JE. Long-term outcome of achalasia treatment: the need for closer follow-up. J Clin Gastroenterol. 1999;28(2):125–30.CrossRefGoogle Scholar
  32. 32.
    Karamanolis G, Sgouros S, Karatzias G, Papadopoulou E, Vasiliadis K, Stefanidis G, Mantides A. Long-term outcome of pneumatic dilation in the treatment of achalasia. Am J Gastroenterol. 2005;100(2):270–4.CrossRefGoogle Scholar
  33. 33.
    Zerbib F, Thétiot V, Richy F, Benajah DA, Message L, Lamouliatte H. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol. 2006;101(4):692–7.CrossRefGoogle Scholar
  34. 34.
    Eckardt VF, Gockel I, Bernhard G. Pneumatic dilation for achalasia: late results of a prospective follow up investigation. Gut. 2004;53(5):629–33.CrossRefGoogle Scholar
  35. 35.
    Alderliesten J, Conchillo JM, Leeuwenburgh I, Steyerberg EW, Kuipers EJ. Predictors for outcome of failure of balloon dilatation in patients with achalasia. Gut. 2011;60:10–6.CrossRefGoogle Scholar
  36. 36.
    Vaezi MF, Baker ME, Achkar E, Richter JE. Timed barium oesophagram: better predictor of long term success after pneumatic dilation in achalasia than symptom assessment. Gut. 2002;50(6):765–70.CrossRefGoogle Scholar
  37. 37.
    Gockel I, Junginger T. The value of scoring achalasia: a comparison of current systems and the impact on treatment—the surgeon’s viewpoint. Am Surg. 2007;73(4):327–31.PubMedGoogle Scholar
  38. 38.
    Stavropoulos SN, Friedel D, Modayil R, Iqbal S, Grendell JH. Endoscopic approaches to treatment of achalasia. Ther Adv Gastroenterol. 2012;107(12):1817–25.Google Scholar
  39. 39.
    Moonen A, Boeckxstaens G. Current diagnosis and management of achalasia. J Clin Gastroenterol. 2014;48(6):484–90.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Krill JT, Naik RD, Vaezi MF. Clinical management of achalasia: current state of the art. Clin Exp Gastroenterol. 2016;9:71.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Katzka DA, Castell DO. Review article: an analysis of the efficacy, perforation rates and methods used in pneumatic dilation for achalasia. Aliment Pharmacol Ther. 2011;34(8):832–9.CrossRefGoogle Scholar
  42. 42.
    Boeckxstaens GE, Annese V, Varannes SB, Chaussade S, Costantini M, Cuttitta A, Elizalde JI, Fumagalli U, Gaudric M, Rohof WO, Smout AJ. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. N Engl J Med. 2011;364(19):1807–16.CrossRefGoogle Scholar
  43. 43.
    Metman EH, Lagasse JP, d’Alteroche L, Picon L, Scotto B, Barbieux JP. Risk factors for immediate complications after progressive pneumatic dilation for achalasia. Am J Gastroenterol. 1999;94(5):1179–85.CrossRefGoogle Scholar
  44. 44.
    Jung HE, Lee JS, Lee TH, Kim JN, Hong SJ, Kim JO, Kim HG, Jeon SR, Cho JY. Long-term outcomes of balloon dilation versus botulinum toxin injection in patients with primary achalasia. Korean J Intern Med. 2014;29(6):738–45.CrossRefGoogle Scholar
  45. 45.
    O’Connor JB, Singer ME, Imperiale TF, Vaezi MF, Richter JE. The cost-effectiveness of treatment strategies for achalasia. Dig Dis Sci. 2002;47(7):1516–25.CrossRefGoogle Scholar
  46. 46.
    Moonen A, Annese V, Belmans A, Bredenoord AJ, des Varannes SB, Costantini M, Dousset B, Elizalde JI, Fumagalli U, Gaudric M, Merla A. Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy. Gut. 2016;65(5):732–9.CrossRefGoogle Scholar

Copyright information

© SAGES 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology, Hepatology and NutritionVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of Internal MedicineVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations